Katlein Franca, MD, is a dermatologist and clinical associate professor of Dermatology & Cutaneous Surgery and Psychiatry & Behavioral Sciences at the University of Miami. Doctors use a process of ...

For over a decade, Ruth has written for multiple outlets providing patient education, including Health. She has written for health student education companies, collaborating on an anatomy textbook ...

Please provide your email address to receive an email when new articles are posted on . Omlyclo is approved to treat the same four conditions as omalizumab. There are now three doses/solutions of ...

On December 3, 2025, Celltrion announced that the FDA has approved a new dose of OMLYCLO (omalizumab-igec), the first and only biosimilar designated as interchangeable with Genentech and Novartis’s ...

During the winter, you may struggle to feel warm no matter how much you bundle up. But some people actually break out in hives when exposed to cold, whether they’re outdoors in the winter, walking ...

Add Yahoo as a preferred source to see more of our stories on Google. Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, particularly ...

Novartis has secured FDA approval for its BTK inhibitor remibrutinib (Rhapsido) for the treatment of chronic spontaneous urticaria. Remibrutinib is the sixth BTK inhibitor to market in the US, and the ...

Novartis has scored the FDA’s approval for a second BTK inhibitor that’s for a non-cancer indication, teeing off a potential competition with Sanofi down the line. The FDA has blessed Novartis’ ...

Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing patient access and competition. A potential new biosimilar to Xolair ...